P1022 RANDOMIEZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS SPARING REGIMEN

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。对于在怀孕期间开始联合抗逆转录病毒治疗的妇女，最佳策略尚不清楚。在怀孕期间开始抗逆转录病毒疗法的艾滋病毒感染妇女目前正在接受各种初步抗逆转录病毒疗法的治疗。来自ACTG 367的数据表明，到妊娠晚期，在妊娠期间开始抗逆转录病毒治疗的HIV感染孕妇中，38%正在接受以蛋白酶抑制剂为基础的方案，奈非那韦是最常用的药物，15%正在接受蛋白酶抑制剂保留方案，含3种药物。接受以奈韦拉平为基础的方案的妇女比例随着时间的推移而增加，在2000年7月至2001年2月的分娩中达到28%。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The optimal strategy is not known for women who initiate combination antiretroviral therapy during pregnancy. HIV-infected women who begin antiretroviral therapy during pregnancy are currently being treated with a variety of initial antiretroviral regimens. Data from ACTG 367 indicate that by the third trimester, 38% of HIV-invected pregnant women who initiate antiretroviral therapy during pregnancy are taking a protease inhibitor based regimen with nelfinavir as the most commen agent used and 15% are on a protease inhibitor-sparing regimen with 3 drugs. The proportion of women who received nevirapine-based regiments has increased over time, reaching 28% among deliveries from 7/00 to 2/01.